![Anders Ohberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anders Ohberg
Directeur/Membre du Conseil chez
CINCLUS PHARMA HOLDING AB
Profil
Anders Ohberg currently works at Norrlandsfonden, as Chairman, Cinclus Pharma Holding AB, as Independent Non-Executive Director from 2016, and Regulus Pharma Fas i AB, as Director.
Mr. Ohberg also formerly worked at PTC Therapeutics, Inc., as Medical Director from 2023 to 2025.
Mr. Ohberg received his graduate degree from the University of Uppsala.
Postes actifs de Anders Ohberg
| Sociétés | Poste | Début |
|---|---|---|
| CINCLUS PHARMA HOLDING AB | Directeur/Membre du Conseil | 01/01/2016 |
Norrlandsfonden
 Norrlandsfonden Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Président | - |
Regulus Pharma Fas i AB | Directeur/Membre du Conseil | - |
Anciens postes connus de Anders Ohberg
| Sociétés | Poste | Fin |
|---|---|---|
| PTC THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/02/2025 |
Formation de Anders Ohberg
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
27
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
University of Uppsala
 University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Norrlandsfonden
Norrlandsfonden Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
Cinclus Pharma Holding AB
 Cinclus Pharma Holding AB BiotechnologyHealth Technology Operates as a holding company through its subsidiaries develops small molecules for treatment of gastric acid related diseases | Health Technology |
Regulus Pharma Fas i AB |
